C-KIT Antibody Variable Region Optimization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antibody therapeutics targeting C-KIT often face challenges such as reduced target binding affinity due to humanization processes, physical instability, and immunogenicity, limiting their clinical efficacy and development.
Innovation Solution
Development of optimized anti-C-KIT antibodies with specific heavy and light chain variable region sequences that enhance binding specificity and affinity to human and cynomolgus monkey C-KIT, while minimizing immunogenicity and improving biophysical stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If humanization process is applied to rodent-derived antibodies, then immunogenicity is reduced, but target binding affinity is reduced
Solution Approach 1:
The patent applies parameter changes by systematically modifying the amino acid sequences of the antibody variable regions (VH and VL) to optimize both human compatibility and target binding. Specific substitutions at key positions (e.g., framework region residues and CDR residues) are made to reduce immunogenicity while preserving or enhancing affinity for human and cynomolgus monkey C-KIT, as evidenced by the detailed sequence comparisons and binding data presented.
Solution Approach 2:
The patent applies local quality by making targeted amino acid substitutions at specific positions within the antibody variable regions rather than uniform modifications. Different positions receive different treatments: some positions are substituted to reduce immunogenicity (e.g., non-human germline content), while other positions are optimized to maintain or enhance binding affinity. This localized optimization is evident in the detailed sequence specifications and the differential treatment of framework versus CDR regions.
2Reliability
If antibody sequences are optimized for binding affinity, then target binding affinity is improved, but biophysical stability may be compromised
Solution Approach 1:
The patent applies parameter changes by systematically modifying amino acid sequences to simultaneously optimize binding affinity and biophysical stability. Specific substitutions are made at positions that influence both properties, such as framework region residues that affect structural integrity and CDR residues that influence binding. The patent provides evidence of improved stability through reduced aggregation and enhanced solubility while maintaining high affinity binding.
Solution Approach 2:
The patent applies composite materials by creating antibody sequences that integrate multiple functional properties: humanized framework regions for reduced immunogenicity, optimized CDR regions for high affinity binding, and strategically placed stabilizing mutations for improved biophysical properties. The resulting antibody molecules are composite structures that combine these different functional elements into a single optimized therapeutic agent.
Data Source
AI summary
Disclosed herein are antibody molecules binding specifically to C-KIT, antigen-binding portions thereof and medical uses therefor.